Additional file 2: Table S2. of BRCA2 carriers with male breast cancer show elevated tumour methylation

Methylation specific high resolution melting condition and primers (XLSX 36 kb

Additional file 1: Table S1. of BRCA2 carriers with male breast cancer show elevated tumour methylation

REMARK patient flow through study (XLSX 34 kb

Additional file 3: Figure S1. of BRCA2 carriers with male breast cancer show elevated tumour methylation

a) BRCA2 subgroup cluster analysis, b) BRCAX subgroup cluster analysis, c) Numbers and sizes of clusters within BRCA2 and BRCAX subgroups using various correlation coefficient cut-offs (listed on the x-axis), d) age of diagnosis of patient within Cluster A, B and other BRCA2 tumours (DOCX 234 kb

Survival curves demonstrating NY-ESO-1 to be a poor prognostic factor (A) and a predictive marker for benefit from adjuvant chemotherapy (B).

<p>Survival curves demonstrating NY-ESO-1 to be a poor prognostic factor (A) and a predictive marker for benefit from adjuvant chemotherapy (B).</p

Association of MAGE-A1, MAGE-A4 and MAGE-C1 expression and survival in the BR.10 study.

<p>Association of MAGE-A1, MAGE-A4 and MAGE-C1 expression and survival in the BR.10 study.</p

Clinicopathological features associated with CTA expression in two cohorts of patients.

<p>Clinicopathological features associated with CTA expression in two cohorts of patients.</p

Expression of N-ESO-1 and response to neoadjuvant chemotherapy (A).

<p>CR = Complete Response, PR = Partial Response, SD = Stable Disease, PD = Progressive Disease, NA = Not Assessable. Forest plot detailing factors associated with survival in patients who were treated in the post-operative cohort. Sq = Squamous Cell, ADC = Adenocarcinoma, ACT = Adjuvant Chemotherapy (B).</p

Multivariate analysis of factors associated with survival in patients treated with surgery initially.

<p>HR = hazard ratio, ACT = adjuvant chemotherapy, SQ = squamous cell, ADC = adenocarcinoma histology.</p